O

Organovo Holdings

D
ONVO
USD
-0.0006
(-0.1188%)
Market Closed
280.00
Volume
-0.96
EPS
-
Div Yield
-0.368248
P/E
7,751,176.34
Market Cap
Today
-0.1188%
1 Week
-7.770%
1 Month
-13.761%
6 Months
-51.952%
12 Months
-65.680%
Year To Date
-54.136%
All Time
-99.333%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Global Tech Outage Exacerbates Shaky Global Markets

22.07.2024
Economy news

Roche’s Obesity Drug Puts Novo Nordisk and Eli Lilly on Alert

17.07.2024
Stocks news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news

Obesity Pill Pushes Novo Nordisk to 12th Most Valuable Company

08.03.2024
Stocks news
More
Related Instruments
T
TWST
0.97
(2.063%)
USD
C
CDXS
0.09
(2.8846%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
V
VCYT
1.51
(4.4727%)
USD
S
SGMO
0.0617
(7.3584%)
USD
A
ALLO
0.025
(0.8681%)
USD
A
ARCT
0.49
(2.3833%)
USD

Title:
Organovo Holdings

Sector:
Healthcare
Industry:
Biotechnology
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
Do you need help or have a question?
Contact Us